Results 61 to 70 of about 634 (79)

OATP1B1/1B3 deficiency exacerbates hyperbilirubinemia in erythropoietic protoporphyria. [PDF]

Drug Metab Dispos
Gu R, Qin FY, Wang L, Zhang J, Emerson J, Ma Q, Lu J, Anderson KE, Wang J, Ma X.   +9 more
europepmc   +1 more source

Monogenic Syndromes as a Cause of Adverse Drug Reactions in the Russian Population. [PDF]

Int J Mol Sci
Buianova AA, Cheranev VV, Shmitko AO, Vasiliadis IA, Samitova AF, Suchalko ON, Repinskaia ZA, Kuznetsov MI, Belova VA, Korostin DO.   +9 more
europepmc   +1 more source

Case Report: Cholestatic liver disease in the course of erythropoietic protoporphyria associated with renal hypodysplasia and atrial septal defect. [PDF]

Front Pediatr
Lipiński P, Lipniacka A, Klaudel-Dreszler M, Ziółkowska L, Kostrzewa G, Odnoczko E, Wasilewski R, Płoski R, Tylki-Szymańska A.   +8 more
europepmc   +1 more source

New pharmacotherapies for the erythropoietic protoporphyrias: an analysis of trial protocols from a patient perspective. [PDF]

Orphanet J Rare Dis
Dechant C, Wäscher S, Granata F, Gusset N, Pettersson M, Aksözen MH, Höglinger M, Falchetto R, Barman-Aksözen J.   +8 more
europepmc   +1 more source

Inhibition of ABCG2 prevents phototoxicity in a mouse model of erythropoietic protoporphyria. [PDF]

Nat Commun
Zhu J, Qin FY, Lei S, Gu R, Qi Q, Lu J, Anderson KE, Wipf P, Ma X.   +8 more
europepmc   +1 more source

The Histamine Pathway is a Target to Treat Hepatic Experimental Erythropoietic Protoporphyria. [PDF]

Cell Mol Gastroenterol Hepatol
Kuo N, Li P, Cunha JB, Chen L, Shavit JA, Omary MB.   +5 more
europepmc   +1 more source

Nrf2 activators for the treatment of rare iron overload diseases: From bench to bedside. [PDF]

Redox Biol
Dong Y, Zheng M, Ding W, Guan H, Xiao J, Li F.   +5 more
europepmc   +1 more source

Genetics of Gallstones. [PDF]

Genes (Basel)
Pęczuła A, Czaplicki A, Przybyłkowski A.   +2 more
europepmc   +1 more source